Recent diagnostic innovations, such as genetic and biomarker testing, are enabling more accurate detection and treatment of diseases like cancer and Alzheimer’s. In 2024, the use of genetic testing increased by 10%, reflecting a growing acceptance among patients, providers, and health plans. Key drivers of this trend include multicancer early detection (MCED) tests, polygenic risk scores, and blood tests for Alzheimer’s.
In this article, Avalon CEO Bill Kerr, MD, highlights the link between personalized medicine and value-based care, where success is measured by patient outcomes rather than the volume of services provided. By tailoring treatments to each patient’s unique biology, we can enhance early detection, optimize therapy selection, and reduce costs. Although challenges persist in areas such as access, testing consistency, and policy alignment, Dr. Kerr encourages healthcare stakeholders to adopt science-driven strategies that prioritize patients’ needs.
Read the full article in Managed Healthcare Executive
